MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <i>TP53</i> Mutation in Preclinical Models of Colorectal Cancer

Abstract

Our data support that, in wild-type TP53 colorectal cancer cells with ERK and PI3K pathway alterations, MEK blockade results in potent p21 induction, preventing apoptosis to occur. In turn, mTORC1/2 inhibition blocks MEK inhibitor-mediated p21 induction, unleashing apoptosis. Clin Cancer Res; 21(24); 5499-510. ©2015 AACR.